ERBB2 (Ab-1221/1222) Antibody

1. This exceptionally sensitive electrochemical sensing performance, enabled by anionic porphyrin for DNA sequences specific to the HER2 gene, holds significant promise for tumor diagnosis and treatment. PMID: 30340409
2. Researchers demonstrated that mRNA and protein levels of COX2 and HER2 were upregulated in CRC compared to adjacent tissues. COX2 protein levels and nuclear COX2 expression were associated with a poor prognosis for CRC patients. COX2 expression exhibited a positive correlation with HER2 expression. PMID: 29873317
3. In patients with HER2-positive advanced breast cancer who have received extensive prior treatment with anti-HER2 agents and cytotoxic chemotherapy, trastuzumab emtansine (T-DM1) has demonstrated good tolerability and provided a significant progression-free survival of 6 months. Overall survival has not yet been reached. PMID: 29326401
4. The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and further investigation is needed to determine if they act synergistically in the targeted therapy of lung adenocarcinoma. PMID: 29400000
5. While ST6GalI overexpression increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to the vector cell line. Conversely, ST6GalI knockdown had the opposite effects. These findings collectively suggest a functional role of ST6GalI in promoting tumor cell progression and trastuzumab resistance. PMID: 30226606
6. This study demonstrates that miR-495 exerts promotive effects on GC chemosensitivity by inactivating the mTOR signaling pathway through suppression of ERBB2. This provides robust evidence supporting the use of miR-495 as a potential novel target in the chemotherapy of GC. PMID: 30147110
7. In early breast cancer, PIK3CA mutations appear to identify HER2+ patients who are less likely to achieve pCR. The clinical implications of PIK3CA mutations seem to vary between exon 9 and exon 20. This mechanism should be further investigated in future studies. PMID: 29575819
8. HER2 and HER3 expression was detected in 22.2% and 86.1% of samples, respectively. The frequency of EGFR mutation was 45.7% and was not significantly different between stage 0 and IA1 (40.0% and 48.0%, respectively), suggesting that EGFR mutation does not correlate with cancer progression from stage 0 to IA1. PMID: 29473311
9. Studies have demonstrated that the heterogeneity of HER2 expression accelerates the development of metastases, leading to poorer survival in mice with heterogeneous HER2 expression (HER2-60). PMID: 30042341
10. Her-2/neu amplification increases with increasing grade of breast cancer. A high proportion of Her-2/neu gene amplified cases indicates aggressive disease in that region and necessitates large-scale FISH testing, which is the gold standard for equivocal cases on immunohistochemistry. PMID: 30060783
11. Data indicate that the primary mechanism involves p140Cap's ability to interfere with ERBB2-dependent activation of Rac GTPase-controlled pathways. PMID: 28300085
12. A study showed that the expression levels of Gli1 and HER2 were significantly higher in gastric cancer, and they are positively related. HER2 may regulate Gli1 via the Akt-mTOR-p70S6K pathway. PMID: 29321573
13. The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu, along with clinicopathological details, may be helpful in identifying individuals more likely to carry BRCA1 mutations and thus selecting candidates and family members for genetic screening for BRCA1 mutations. PMID: 29567881
14. In current settings, HER2/neu is not considered a prognostic marker in head-and-neck cancers. PMID: 30004046
15. These results suggest that HE4 expression increases in patients with HER2/neu amplification. PMID: 30004048
16. HER2 gene amplification in circulating tumor DNA predicts HER2-positive breast neoplasms' resistance to trastuzumab emtansine. PMID: 29700710
17. Statistical analysis performed in this study did not reveal a significant relationship between HER2 overexpression on the tumor cells and microvessel density in the tumor stroma. PMID: 30334990
18. Data showed a high rate of discordance in matched pairs of primary tumors and metastases, indicating that accurate evaluation of proto-oncogene protein HER-2 (HER2) status is essential before any therapeutic decision. PMID: 30203148
19. HER2 gene amplification occurred during the early stages of gastric cancer and exhibited heterogeneity in several cases. HER2 gene amplification may be involved in tumor progression in early gastric cancer. PMID: 30120594
20. Activating HER2 mutation is present in approximately 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer. PMID: 30094493
21. The results suggest a possible link between tRNALeu overexpression and RSK1/MSK2 activation and ErbB2/ErbB3 signaling, particularly in breast cancer. PMID: 28816616
22. High HER2 expression is associated with metastasis in breast cancer. PMID: 29187405
23. This study confirmed that biosimilar trastuzumab improves the overall response rate when combined with chemotherapy for HER2+ breast cancer. PMID: 30082554
24. The study reveals a gender difference in the prognostic value of concomitant AIB1 and HER2 copy number gain (CNG) in glioma patients, which was largely unnoticed previously. These observations indicate that genetic alterations synergistic with essential aspects of sex determination influence glioma biology and patient outcomes. PMID: 30153912
25. The survival rates in this study are equivalent to documented global rates. Nodal disease burden emerged as the most significant prognostic factor. Additionally, in EBCs, a lack of hormone receptor expression, and in LABC, Her2neu overexpression appear to worsen the outcome. PMID: 30147088
26. Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional level in gastric cancer. PMID: 29987267
27. HER2 overexpression is associated with gastric cancer. PMID: 29938472
28. The ERBB2 oncogene at 17q12 is susceptible to palindromic gene amplification in HER2-positive breast tumors. PMID: 28211519
29. Results indicate that mutation in ERBB2-exon17 was associated with worse survival outcomes in patients with pancreatic neoplasm. [review] PMID: 30227250
30. High HER2 expression and gene amplification are associated with upper tract urothelial carcinomas. PMID: 28755093
31. High HER2 expression is associated with invasion and lymph node metastasis in gastric cancer. PMID: 29970682
32. The basal HER2 phenotype showed poor DFS, but equivalent pCR rates after concurrent neo-adjuvant chemotherapy with trastuzumab. A distinct treatment approach is needed for basal-HER2 type, even for cases that achieved adequate clinical response after neo-adjuvant chemotherapy. PMID: 29971625
33. In the largest series reported to date, patients with HER2-amplified m17 cancers treated with trastuzumab have outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive, supporting the critical role of HER2-directed therapy in this patient population. PMID: 28986743
34. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2. PMID: 29223420
35. The study provides evidence that the hostile environment developed in spheroids plays a key role in the acquisition of resistance to Trastuzumab. This is associated with an increase in the number of breast cancer stem cells as well as a modulation in HER2 expression. PMID: 28722778
36. A major finding of the study is that one in five (20%) patients with breast cancer BM exhibited a receptor discrepancy between the primary tumor and subsequent BM. The most commonly observed changes involved the loss of hormone receptors (ER and/or PR) expression and the gain of HER2 overexpression. PMID: 28975433
37. High HER2 expression is associated with gastric adenocarcinoma. PMID: 29802704
38. Absence of HER2 expression of circulating tumor cells is associated with non-metastatic esophageal cancer. PMID: 30275185
39. HER2 positivity was found in a minority of rectal cancer patients and was not significantly associated with clinicopathologic and molecular characteristics. PMID: 30056472
40. The study discovered a novel enhancer, HER2 gene body enhancer (HGE), in the 3' gene body of HER2. The HGE activates promoters 1 and 2 in trans., and hence the TFAP2C-mediated transcriptional induction of HER2 expression in breast cancer samples. PMID: 29035388
41. ctDNA gene mutation profiles differed among HR/HER2 subtypes of metastatic breast cancer (MBC) patients. By identifying mutations associated with treatment resistance, researchers hope to improve therapy selection for MBC patients who have received multiple lines of treatment. PMID: 29807833
42. It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2-positive gastric cancer. PMID: 29786108
43. HER2 overexpression was evident in nearly 25% of Malaysian patients with locally advanced or metastatic gastric cancer. The overexpression correlated significantly with male gender and diffuse-type tumors. PMID: 28124769
44. There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p=0.004), high Ki-67 expression (p<0.001) and the development of visceral metastasis. PMID: 29779938
45. The authors herein provide the first evidence that the transcriptional repressor Blimp1 is a novel mediator of p130Cas/ErbB2-mediated invasiveness. High Blimp1 expression levels are detected in invasive p130Cas/ErbB2 cells and correlate with metastatic status in human breast cancer patients. PMID: 28442738
46. ERBB2 amplification is a driver of resistance to erlotinib in lung adenocarcinoma. PMID: 28870636
47. Results demonstrated that combining the results of IHC and FISH according to the HER2 testing algorithm is a valuable method for accurately evaluating HER2-positive EMPD. PMID: 29744813
48. Given the lower concordance rates of HER2 IHC score 2/3+ cases compared to HER2 IHC score 0/1+ cases, further research is needed to establish detailed analysis criteria for HER2 IHC score 2+ or 3+. PMID: 28478639
49. HER2 interacts with Beclin 1 in breast cancer cells and inhibits autophagy. Mice with increased basal autophagy due to a genetically engineered mutation in Becn1 are protected from human HER2-driven mammary tumorigenesis. HER2-mediated inhibition of Beclin 1 and autophagy likely contributes to HER2-mediated tumorigenesis. PMID: 29610308
50. These findings suggest that early-stage morphological alterations of HER2-positive BC cells during cancer progression can occur in a manner independent of physical interaction and signaling. PMID: 27599456

HGNC: 3430

OMIM: 137800

KEGG: hsa:2064

STRING: 9606.ENSP00000269571

UniGene: Hs.446352